Last updated: 18 June 2024 at 5:03pm EST

Cintia Piccina Net Worth




The estimated Net Worth of Cintia Piccina is at least $111 Thousand dollars as of 18 June 2024. Cintia Piccina owns over 24,531 units of AlloVir stock worth over $28,337 and over the last 2 years Cintia sold ALVR stock worth over $82,289.

Cintia Piccina ALVR stock SEC Form 4 insiders trading

Cintia has made over 3 trades of the AlloVir stock since 2022, according to the Form 4 filled with the SEC. Most recently Cintia sold 24,531 units of ALVR stock worth $22,814 on 18 June 2024.

The largest trade Cintia's ever made was selling 24,531 units of AlloVir stock on 18 June 2024 worth over $22,814. On average, Cintia trades about 9,577 units every 115 days since 2022. As of 18 June 2024 Cintia still owns at least 38,293 units of AlloVir stock.

You can see the complete history of Cintia Piccina stock trades at the bottom of the page.



What's Cintia Piccina's mailing address?

Cintia's mailing address filed with the SEC is C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, X0, OX14 4RX.

Insiders trading at AlloVir

Over the last 4 years, insiders at AlloVir have traded over $46,273,050 worth of AlloVir stock and bought 5,850,170 units worth $60,516,413 . The most active insiders traders include Sciences, Inc. Gilead, Group, Llc Green Jeremy Red..., and Ansbert Gadicke. On average, AlloVir executives and independent directors trade stock every 9 days with the average trade being worth of $43,527. The most recent stock trade was executed by Diana Brainard on 21 May 2024, trading 5,149 units of ALVR stock currently worth $4,068.



What does AlloVir do?

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.



What does AlloVir's logo look like?

AlloVir, Inc. logo

Complete history of Cintia Piccina stock trades at Adaptimmune Therapeutics Plc and AlloVir

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
18 Jun 2024 Cintia Piccina
Chief Commercial Officer
Sale 24,531 $0.93 $22,814
18 Jun 2024
38,293
31 Jan 2023 Cintia Piccina
Chief Commercial Officer
Sale 11,890 $1.87 $22,234
31 Jan 2023
19,535
1 Aug 2022 Cintia Piccina
Chief Commercial Officer
Sale 21,040 $1.77 $37,241
1 Aug 2022
34,824


AlloVir executives and stock owners

AlloVir executives and other stock owners filed with the SEC include: